Key result
LNA SSOs effectively induce exon skipping in vitro, with a 13-mer demonstrating highest efficacy.
Why the study?
Few examples exist of modulation of pre-mRNA splicing using locked nucleic acid antisense oligonucleotides, and no systematic study has addressed optimal design of LNA-based splice-switching oligonucleotides.
Does the design (length, number of LNAs, melting temperature) of LNA SSOs affect their ability to induce exon skipping in vitro?
Does the design (length, number of LNAs, melting temperature) of LNA SSOs affect their ability to induce exon skipping in vitro?
Answers are grounded in this paper and cite their sources.
The number of LNAs, melting temperature, and length are key determinants for designing efficient LNA SSOs to induce exon skipping in vitro.
Antisense-mediated modulation of pre-mRNA splicing is an attractive therapeutic strategy for genetic diseases. Currently, there are few examples of modulation of pre-mRNA splicing using locked nucleic acid (LNA) antisense oligonucleotides, and, in particular, no systematic study has addressed the optimal design of LNA-based splice-switching oligonucleotides (LNA SSOs). Here, we designed a series of LNA SSOs complementary to the human dystrophin exon 58 sequence and evaluated their ability to induce exon skipping in vitro using reverse transcription-polymerase chain reaction. We demonstrated that the number of LNAs in the SSO sequence and the melting temperature of the SSOs play important roles in inducing exon skipping and seem to be key factors for designing efficient LNA SSOs. LNA SSO length was an important determinant of activity: a 13-mer with six LNA modifications had the highest efficacy, and a 7-mer was the minimal length required to induce exon skipping. Evaluation of exon skipping activity using mismatched LNA/DNA mixmers revealed that 9-mer LNA SSO allowed a better mismatch discrimination. LNA SSOs also induced exon skipping of endogenous human dystrophin in primary human skeletal muscle cells. Taken together, our findings indicate that LNA SSOs are powerful tools for modulating pre-mRNA splicing.
No takes yet. Share an insight, caveat, or question.
Shimo et al. (2014) studied Genetic diseases. Locked nucleic acid-based splice-switching oligonucleotides (LNA SSOs) was evaluated on Ability to induce exon skipping in vitro. Locked nucleic acid-based splice-switching oligonucleotides effectively induced exon skipping in vitro, with a 13-mer containing six LNA modifications demonstrating the highest efficacy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: